Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (TLX) is a commercial-stage biopharmaceutical entity specializing in the creation and distribution of advanced radiopharmaceuticals. Its core mission is to develop both diagnostic agents and therapeutic treatments for cancer and rare diseases across key international markets, including Australia, Belgium, Japan, Switzerland, and the United States. Among its currently available products, Telix offers Illuccix, designed for the management of prostate cancer, and TLX66-CDx, which serves as an imaging agent for osteomyelitis. The company also maintains a robust pipeline of investigational candidates aimed at various conditions: Prostate Cancer: TLX591, a radio antibody-drug conjugate, and TLX592, a candidate for targeted alpha therapy. Renal (Kidney) Cancer: TLX250-CDx, intended for both diagnosis and treatment, and TLX250, specifically for clear cell renal cell carcinoma. Brain Cancer: This includes TLX101-CDx and TLX101, which targets glioblastoma. Bone Marrow Conditioning: TLX66-CDx and TLX66 are being explored. Soft Tissue Sarcoma: TLX300-CDx and TLX300 are under development for diagnosis and treatment. Founded in 2015, Telix Pharmaceuticals Limited is based in North Melbourne, Australia.